Do you want to read an article? Please log in or register.
A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis
Further Publications
COMMENTED
Related content
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial
Diabetes Obes Metab.
Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A; EMPA-REG H2H-SU trial investigators
doi: 10.1111/dom.13457.
Type 2 Diabetes
Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes
Diabetes Obes Metab.
Philis-Tsimikas A, Billings LK, Busch R, Morales Portillo C, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S
doi: 10.1111/dom.13666.
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose
Diabetes.
Abdul-Ghani M, Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo RA
doi: 10.2337/db17-0055.
Type 2 Diabetes
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
Lancet Diabetes Endocrinol
Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, Gustafsson F, Faber J, Malik ME, Fosbøl EL, Bruun NE, Forman JL, Jensen LT, Møller JE, Schou M
doi: 10.1016/S2213-8587(20)30382-X
Diabetes - General
Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction
J Am Coll Cardiol
Santos-Gallego CG, Vargas-Delgado AP, Requena JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Cordero AR, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ, EMPA-TROPISM (ATRU-4) investigators.
doi: 10.1016/j.jacc.2020.11.008
Type 2 Diabetes
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
Cardiovasc Diabetol
Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K, EMBLEM Investigators.
doi: 10.1186/s12933-021-01295-6
Type 2 Diabetes
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
J Am Soc Nephrol.
Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators
doi: 10.1681/ASN.2018010103.
Diabetes - General
Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
Diabet Med.
Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J
doi: 10.1111/dme.13629.
COMMENTED
Type 2 Diabetes
Effects of Empagliflozin on Erythropoiesis in Patients with Type 2 Diabetes - data from a randomized, placebo controlled study
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab
Thiele K, Rau M, Hartmann NK, Möllmann J, Jankowski J, Böhm M, Keszei AP, Marx N, Lehrke M
doi: 10.1111/dom.14517